EIT Health Catapult: 21 startups reach the finalist rank
Catapult, the acceleration program powered by EIT Health held its semi-finals from 1st to 3rd December. In front of the biggest sponsors and companies of the industry, the semi-finalists had the chance to pitch their solution and 21 of them reached the podium and finals, happening during the EIT Health Summit on 24th & 25th May 2022.Discover the finalists
Catapult: review of a unique program
EIT Health Catapult is powered by the EIT Health and supports, each year, the most promising Medtech, Biotech and Digital Health startups. A prestigious network and program for early stage innovators.
EIT Health Catapult is a unique competition and training program for the best Medtech, Biotech and Digital Health European startups. The participants receive high-quality training in business modelling and planning, investment deal negotiation and specialised pitch preparation. The program is also a unique opportunity to access Europe’s top healthcare experts and investors.
Since 2016, the program recorded:
EIT Health Catapult benefit from world-wide healthcare sponsors such as Lusiadas Saude, AWS, Nasdaq and AstraZeneca, eg technology, McDermott Will & Emery, Merck who have all sponsored additional prizes that will provide the winners with their expertise and support. Tremendous actors giving to the program, winners and participants an outstanding visibility. Medical Valley and Cap Digital are the main partners running the program for the EIT Health.
The final of EIT Health Catapult will be held during EIT Health Summit happening in Stockholm on 24th & 25th May 2022.Learn more
Applications open for EIT Health Catapult 2022 in January. Find out more.
Meet the finalists
We are proud to introduce the 21 winners of the semi-finals. Meet the disruptive and promising solutions for Medtechs, Biotechs and Digital Health.
Three podium finalists from each category will compete on stage during the final. The runners-up are invited to the final to have the opportunity to pitch.
Onena Medicines (Spain): makes antibody medicines that force drug resistant cancer stem cells to permanently grow old, rendering them incapable of sustaining and spreading cancer.
SideROS (France): a preclinical stage biotech, developing small molecules targeting iron metabolism to fight cancer resistance, responsible for relapse and metastasis.
SolasCure (UK): makes Aurase®, a hydrogel containing a safe, active, highly specific enzyme, isolated and cloned from medical maggots which promotes faster wound cleaning.
Arthex Biotech (Spain): a preclinical stage life sciences company focused on developing the next generation of RNA therapies to treat myotonic Dystrophy Type1.
Asylia Diagnostics (Belgium): an artificial intelligence enabled in vitro diagnostics company, focused on optimising the clinical management of cancer patients treated by immune checkpoint inhibitors.
Limula (Switzerland): saves lives by enabling widespread access to the latest generation of personalised cancer treatments.
myNEO (Belgium): helps to unlock the potential of immunotherapy for every cancer patient using innovative biosimulation and AI heuristics.
Leuko (Spain): develops PointCheck™, a device that can monitor white blood cells non-invasively. White blood cell monitoring is a first-line indicator in cancer chemotherapy and infection detection.
Luminate Medical (Ireland): develops a novel technology to manage off-target drug delivery. Their product, Lily, provides a portable, patient-focused treatment to prevent chemo induced hair loss.
Thinksono (Germany): created the world’s first software for automatic detection of deep vein thrombosis (DVT). DVT is the number one cause of preventable hospital death.
Arthrosave (Netherlands): offers a revolutionary procedure to preserve the knee joint for people with osteoarthritis, significantly reducing pain and improving function.
BeFC (France): makes electricity with papers and enzymes. Their paper biofuel cells provide an eco-friendly and sustainable energy solution for low-power medical devices.
FeelTect (Ireland): has developed Tight Alright, the first connected health platform for monitoring compression therapy; improving healing, reducing costs, and facilitating self-managed treatment.
Orixha (France): aims to bring liquid ventilation’s clinical benefits to the ICUs to save critical care patients. Vent2Cool is developed to shield the brain and heart from reperfusion injury.
AZmed (France): develops AI-powered solutions improving radiologist’s productivity and diagnostics quality. Their first product Rayvolve detects all types of fractures on X-rays.
Brightlobe (UK): has invented patent-pending technology that can assess and support a child’s brain development using clinically validated mobile games.
Ebenbuild (Germany): develops simulation/AI software to generate data about patients’ lungs, enabling doctors to provide better personalised therapy for Acute Respiratory Distress Syndrome (ARDS).
Amara Therapeutics (Ireland): develops a prescription digital therapeutic platform, RiSolve, for the treatment of Overactive Bladder.
Exheus (Spain): the first direct-to-consumer gene expression report that helps to optimise people’s health in a highly personalised way, by sequencing the RNA from a blood sample.
Heaxel (Italy): develops icone, a connected network of robots which aids the neurorehabilitation of stroke patients from hospital to home.
Mentalis (Germany): provides evidence-based digital aftercare that combines algorithm-driven app-therapy and instant psychological tele-support.